Astellas Pharma ends development of dust mite allergy vaccine
Astellas Pharma will book an impairment loss of just under USD 400m due to three less-than-successful drug programs. One of the programs, concerning a DNA vaccine against dust mite-induced allergic rhinitis, has now been terminated.
by christian bundgaard, translated by daniel pedersen
Japanese Astellas Pharma has been less than fortunate when it comes to its clinical development programs.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Astellas shakes structure of R&D division
For subscribers
